Adipokine dysregulation and subclinical inflammation are putative diabetogenic features of adiposity. However, while alterations in adipokines/inflammatory proteins can predict incident type 2 diabetes in longitudinal studies (1-3), evidence for causality is generally hindered by two limitations. First, there is a relative paucity of human data linking changes in adipokines/inflammatory proteins with changes in insulin sensitivity and b-cell function over time, as might be expected for causal mediators. Second, because obesity-induced changes in circulating proteins do not occur in isolation, the precise elucidation of causal mediators ideally requires consideration of multiple adipokines/inflammatory proteins simultaneously (as opposed to individually, as typically occurs in studies). Thus, to address these limitations, we evaluated changes over 2 years in adipokines (adiponectin, chemerin, retinol binding protein 4 [RBP-4]) and inflammatory proteins (C-reactive protein [CRP], plasminogen activator inhibitor 1 [PAI-1]) in relation to changes in insulin sensitivity, b-cell function, and glycemia in women with varying degrees of recent gestational dysglycemia and hence a range of future risk of diabetes.
https://doi.org/10.2337/dc17-0781
Adipokine dysregulation and subclinical inflammation are putative diabetogenic features of adiposity. However, while alterations in adipokines/inflammatory proteins can predict incident type 2 diabetes in longitudinal studies (1-3), evidence for causality is generally hindered by two limitations. First, there is a relative paucity of human data linking changes in adipokines/inflammatory proteins with changes in insulin sensitivity and b-cell function over time, as might be expected for causal mediators. Second, because obesity-induced changes in circulating proteins do not occur in isolation, the precise elucidation of causal mediators ideally requires consideration of multiple adipokines/inflammatory proteins simultaneously (as opposed to individually, as typically occurs in studies). Thus, to address these limitations, we evaluated changes over 2 years in adipokines (adiponectin, chemerin, retinol binding protein 4 [RBP-4]) and inflammatory proteins (C-reactive protein [CRP] , plasminogen activator inhibitor 1 [PAI-1]) in relation to changes in insulin sensitivity, b-cell function, and glycemia in women with varying degrees of recent gestational dysglycemia and hence a range of future risk of diabetes.
In this study, 339 women underwent a glucose challenge test (GCT) and oral glucose tolerance test (OGTT) in pregnancy, followed by repeat OGTT and measurement of adiponectin (Millipore), chemerin (Millipore), RBP-4 (ALPCO), CRP (Dade Behring), and PAI-1 (Invitrogen) at both 1 year and 3 years postpartum. The study protocol has been previously described in detail (4,5). On each OGTT, insulin sensitivity/ resistance was measured by Matsuda index and HOMA of insulin resistance (HOMA-IR), and b-cell function was measured by the Insulin Secretion-Sensitivity Index-2 and insulinogenic index/HOMA-IR (4,5). The antepartum GCT/OGTT identified four gestational glucose tolerance groups (gestational diabetes mellitus, gestational impaired glucose tolerance, abnormal GCT with normal OGTT, normal GCT/OGTT), each of which predicts distinct trajectories of future risk of diabetes (5). On multiple linear regression analyses (Table 1) , none of the adipokines/ inflammatory proteins or their changes predicted b-cell function at 3 years (models A and B). Adiponectin at 1 year predicted insulin sensitivity (Matsuda index) at 3 years, while PAI-1 at 1 year and its change from 1 to 3 years were negative predictors (model C). The same predictors emerged for HOMA-IR, in addition to CRP at 1 year and its change from 1 to 3 years (model D). For both fasting and 2-h glucose at 3 years (models E and F), significant independent predictors were the respective glucose measurement at baseline, BMI at 1 year, and change in BMI from 1 to 3 years. Of note, although weight gain is associated with both increased CRP and insulin resistance, the change in CRP was itself independently and inversely associated with HOMA-IR and fasting glucose at 3 years, likely reflecting the impact of adjustment for concurrent change in BMI and the other adipokines/inflammatory proteins. Finally, on logistic regression analysis with the same covariates, the only predictors of prediabetes/diabetes at 3 years were glucose intolerance at 1 year (odds ratio 8.12, 95% CI 3.98-16.56), BMI at 1 year (1.09, 1.02-1.16), and change in BMI (1.30, 1.05-1.59).
Thus, in fully adjusted models simultaneously evaluating all of the adipokines/ inflammatory proteins and their changes over time, the dominant independent predictors of all of the metabolic outcomes were BMI at 1 year and its change from 1 to 3 years. The impact of adiposity on risk of diabetes in this population does not appear to be mediated by changes in adiponectin, chemerin, RBP-4, CRP, or PAI-1. No potential conflicts of interest relevant to this articles were reported. Author Contributions. R.R., P.W.C., A.J.H., M.S., and B.Z. designed and implemented the study. R.R. and C.Y. contributed to the analysis plan and interpretation of the data. C.Y. performed the statistical analyses. R.R. wrote the first draft. All authors critically revised the manuscript for important intellectual content. All authors approved the final manuscript. R.R. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Each of these six multiple linear regression models included the covariates age, ethnicity, family history of diabetes, duration of breastfeeding, BMI at 1 year, change in BMI from 1 to 3 years, the measure of the respective outcome variable at 1 year, and both the 1-year measure and change from 1 to 3 years for all of the following: adiponectin, chemerin, RBP-4, CRP, and PAI-1. IGI, insulinogenic index; ISSI-2, Insulin Secretion-Sensitivity Index-2.
